Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Biosite Charts. Click Here for more Biosite Charts.](/p.php?pid=staticchart&s=N%5EBSTE&p=8&t=15)
European and U.S. Clinicians to Present at European Stroke
Conference
Recognized Stroke Experts to Provide Clinical Data on the Triage(R) Stroke
Panel
SAN DIEGO, April 8 /PRNewswire-FirstCall/ -- Biosite(R) Incorporated
(NASDAQ:BSTE) today announced that European and U.S. research clinicians will
present data from clinical studies conducted using Biosite's Triage Stroke
Panel at the 14th Annual European Stroke Conference, to be held May 25 through
28, 2005 in Bologna, Italy at the Palazzo della Cultura et dei Congressi. The
symposium, "A New Paradigm in Emergency Stroke Diagnosis," will take place May
27, 2005 from 6:00 p.m. to 7:30 p.m. (local), or 12:00 p.m. to 1:30 p.m.
Eastern Daylight Time, and will be webcast through Biosite's website at
http://www.biosite.com/.
Dr. Werner Hacke, University of Heidelberg will chair the symposium. Other key
opinion leaders to be featured in the symposium include Dr. Daniel Laskowitz,
Duke University Medical Center; Dr. Joan Montaner, Vall d'Hebron Hospital,
Barcelona, Spain; Dr. Christian Berger, University of Heidelberg; Dr. Patrik
Michel, University Hospital, Lausanne, Switzerland; Dr. Philip Bath, University
of Nottingham, United Kingdom; Dr. Edward Jauch, University of Cincinnati
College of Medicine; Dr. Marc Freysz, University Hospital, Dijon, France; Dr.
Patrick Sauval, Service d'Aide Medicale Urgente, Paris, France; Dr. Salvatore
Di Somma, Sant'Andrea Hospital, Rome, Italy; and Dr. Marco Fiorelli, University
Hospital La Sapienza, Rome, Italy.
Biosite filed a Premarket Approval Application for the Triage Stroke Panel with
the U.S. Food and Drug Administration (FDA) in December 2004. Data from 15
clinical sites and approximately 2,000 patients were included in the clinical
studies submitted to the FDA. The data that will be presented at the symposium
are a subset of the data submitted to the FDA.
A link to the live audio webcast and presentations can be accessed through the
Biosite website, http://www.biosite.com/. The Biosite presentation will be
archived on the website for 21 days in the Investor and Media section under
Events Calendar.
About Biosite Incorporated
A leader in the drive to advance diagnosis, Biosite Incorporated is a
research-based company dedicated to the discovery and development of novel
protein-based diagnostics that improve a physician's ability to diagnose
debilitating and life-threatening diseases. Through combined expertise in
diagnostic discovery and commercialization, Biosite is able to access potential
markers of disease, identify proteins with high diagnostic utility, develop and
commercialize products and educate the medical community on new diagnostic
approaches, thereby benefiting patients. Biosite's Triage(R) rapid diagnostics
are used in approximately 50 percent of U.S. hospitals and in more than 50
international markets for toxicology screening and diagnosis of infectious and
cardiovascular disease. Information on Biosite can be found at
http://www.biosite.com/.
Except for the historical information presented herein, matters discussed in
this press release are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including but not
limited to statements that are preceded by, followed by, or that include the
words "will"; "believes"; "should"; "intends"; "anticipates"; "plans";
"expects"; "estimates"; or similar statements are forward-looking statements.
Risks and uncertainties include risks that FDA clearance for the Triage Stroke
Panel will be delayed or rejected, uncertainties related to the regulatory
scrutiny that will be applied to the Triage Stroke Panel's MultiMarker
Index(TM) feature, risks regarding the discovery and product development
process generally, and risks associated with the commencement of manufacturing
the Triage Stroke Panel on a commercial scale. Other risks and uncertainties
that may impact the Company's business generally include risks associated with
the introduction of competitive products from companies with greater capital
and resources, expansion or development of a direct sales effort in domestic
and international markets, and risks and expenses associated with litigation,
contract disputes, patent conflicts, product recalls, manufacturing
constraints, backlog, delays or inefficiencies, shipment problems, seasonal
customer demand, the timing of significant orders, changes in reimbursement
policies, regulatory changes, competitive pressures on average selling prices,
and the other risks including those detailed in the Company's most recent
Annual Report on Form 10-K, and other SEC filings. The Company disclaims,
however, any intent or obligation to update these forward-looking statements.
Copies of the Company's public disclosure filings are available from the
Investor Relations department.
Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered
trademarks of Biosite Incorporated. The Company's logo is a trademark of
Biosite Incorporated.
DATASOURCE: Biosite Incorporated
CONTACT: Nadine Padilla, Vice President, Corporate and Investor
Relations of Biosite Incorporated, +1-858-455-4808, ext. 3187,
Web site: http://www.biosite.com/
Company News On-Call: http://www.prnewswire.com/comp/116737.html